Compugen (CGEN) Cash & Equivalents (2009 - 2026)

Compugen has reported Cash & Equivalents for 18 years, with the latest figure at $12.4 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $12.4 million, down 14.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.4 million (down 14.68% YoY), and the FY2025 annual result was $90.6 million, up 396.99% from the prior year.
• Cash & Equivalents declined to $12.4 million in Q1 2026, from $90.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $106.8 million in Q1 2022 and troughed at $6.5 million in Q2 2025.
• A 5-year average of $35.6 million and a median of $14.6 million in 2025 frame the typical range for Cash & Equivalents.
• The widest annual swing landed in 2024, when Cash & Equivalents slumped 84.9%; it then soared 396.99% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $11.1 million in 2022, then grew by 25.6% to $13.9 million in 2023, then soared by 31.24% to $18.2 million in 2024, then soared by 396.99% to $90.6 million in 2025, then plunged by 86.27% to $12.4 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $12.4 million in Q1 2026, $90.6 million in Q4 2025, and $7.5 million in Q3 2025.